MyFinsight
Home
Blog
About
Contact
Download
Download image
Syfovre
$586,934K
(-4.07%↓ Y/Y)
Empaveli Pegcetacoplan
$102,449K
(4.44%↑ Y/Y)
Product
$689,383K
(-2.90%↓ Y/Y)
Licensing And Other
Revenue
$314,399K
(340.25%↑ Y/Y)
Revenue
$1,003,782K
(28.46%↑ Y/Y)
Net operating
income/(loss)
$55,427K
(133.60%↑ Y/Y)
Interest income
$13,143K
(2.90%↑ Y/Y)
Total operating
expenses
$948,355K
(0.21%↑ Y/Y)
Net income/(loss)
before taxes
$24,110K
(112.26%↑ Y/Y)
Foreign currency
translation
$1,098K
(407.56%↑ Y/Y)
Unrealized gain/(loss) on
pension plans
-$107K
Interest expense
$44,327K
(9.74%↑ Y/Y)
Other expense, net
-$133K
(93.87%↑ Y/Y)
Selling, general and
administrative
$550,265K
(9.82%↑ Y/Y)
Research and development
$295,854K
(-9.68%↓ Y/Y)
Cost of sales
$102,236K
(-13.16%↓ Y/Y)
Net income/(loss)
$22,388K
(111.31%↑ Y/Y)
Total other
comprehensive income/(loss)
$1,205K
(414.96%↑ Y/Y)
Income tax expense
$1,722K
(48.19%↑ Y/Y)
Comprehensive income/(loss),
net of tax
$23,593K
(111.94%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)